Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Biology Laboratory, |
RCV001281144 | SCV001425101 | pathogenic | Saldino-Mainzer syndrome | 2020-02-01 | criteria provided, single submitter | research | |
Gene |
RCV001751516 | SCV001986583 | uncertain significance | not provided | 2019-07-17 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29801666) |
Labcorp Genetics |
RCV001281144 | SCV004538974 | uncertain significance | Saldino-Mainzer syndrome | 2023-09-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 325 of the IFT140 protein (p.Glu325Asp). This variant is present in population databases (no rsID available, gnomAD 0.006%). This missense change has been observed in individual(s) with IFT140-related conditions (PMID: 29801666). ClinVar contains an entry for this variant (Variation ID: 974394). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt IFT140 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |